{"filing":{"accession_number":"0001213900-26-077364","cik":"0001596812","ticker":"ENLV","company_name":"Enlivex Ltd.","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"ea029772501-6k_enlivex.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1596812/000121390026077364/ea029772501-6k_enlivex.htm"},"events":[{"id":17497,"run_id":15672,"accession_number":"0001213900-26-077364","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The press release announces FDA grant of Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra™ in age-related knee osteoarthritis. This is a material regulatory milestone that accelerates clinical development and provides a pathway to expedited approval, representing a significant operational and strategic advancement for the company's lead therapeutic program. While not fitting a discrete named event type, this regulatory designation is clearly operational/strategic in nature and material to investors assessing the company's development trajectory and commercial prospects.","company_name":"Enlivex Ltd.","ticker":"ENLV","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":[{"id":15995,"accession_number":"0001213900-26-077364","item_number":"EX-99.1","item_title":"ea029772501_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces FDA grant of Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra™ in age-related knee osteoarthritis. This is a material regulatory milestone that accelerates clinical development and provides a pathway to expedited approval, representing a significant operational and strategic advancement for the company's lead therapeutic program. While not fitting a discrete named event type, this regulatory designation is clearly operational/strategic in nature and material to investors assessing the company's development trajectory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:01:50.336442+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15995,"accession_number":"0001213900-26-077364","item_number":"EX-99.1","item_title":"ea029772501_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces FDA grant of Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra™ in age-related knee osteoarthritis. This is a material regulatory milestone that accelerates clinical development and provides a pathway to expedited approval, representing a significant operational and strategic advancement for the company's lead therapeutic program. While not fitting a discrete named event type, this regulatory designation is clearly operational/strategic in nature and material to investors assessing the company's development trajectory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:01:50.336442+00:00","company_name":"Enlivex Ltd.","ticker":"ENLV","filing_date":"2026-07-13"}]}